Skip to main content
MedPathMedPath Home
Clinical Trials/NCT00227435
NCT00227435
Completed
Phase 1

A Phase I/II Double-Blind, Dose Escalation Study to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of Val-mCyd (NM283) in Adults With Chronic Hepatitis C

Merck Sharp & Dohme LLC0 sitesFebruary 2003
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsChronic Hepatitis C

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Chronic Hepatitis C
Sponsor
Merck Sharp & Dohme LLC
Status
Completed
Last Updated
10 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

This study was conducted to determine the safety, tolerance, pharmacokinetics and antiviral activity of val-mCyd at doses ranging from 50 mg to 800 mg per day.

Registry
clinicaltrials.gov
Start Date
February 2003
End Date
July 2004
Last Updated
10 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • •Documented clinical history of chronic hepatitis C and compensated liver disease
  • •No antiviral treatment for hepatitis C in the 6 months prior to the Screening visit
  • •Other protocol-defined inclusion criteria may apply.

Exclusion Criteria

  • •Patient is pregnant or breastfeeding
  • •Patient is co-infected with HBV or HIV
  • •Other protocol-defined exclusion criteria may apply.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Terminated
Phase 1
A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Multiple Doses of Orally Administered JNJ-53718678 in Infants Hospitalized With Respiratory Syncytial Virus (RSV) InfectionRespiratory Syncytial Virus InfectionsVirus Diseases
NCT02593851Janssen Sciences Ireland UC45
Completed
Phase 1
Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of the Monoclonal Antibody PGT121.414.LS Administered Alone and in Combination With VRC07-523LS Via Intravenous or Subcutaneous Infusions in Healthy, HIV-uninfected Adult ParticipantsHIV Infections
NCT04212091National Institute of Allergy and Infectious Diseases (NIAID)33
Completed
Phase 1
Study to Assess Safety,Tolerability,Pharmacokinetics & Antiviral Activity of JTK-853 in Hepatitis C Virus Genotype 1 Infected SubjectsHepatitis C Virus Infection, Response to Therapy of
NCT01473056Akros Pharma Inc.29
Completed
Phase 1
Safety, Pharmacokinetics,and Antiviral Activity of RV299 Against Respiratory Syncytical Virus (RSV)Respiratory Syncytial Virus (RSV)
NCT06067191Pfizer82
Completed
Phase 2
This Trial Evaluates Safety, Pharmacokinetic Profile and Anti-viral Response of BI 207127 and BI 201335 for Patients With Chronic Hepatitis CHepatitis C, Chronic
NCT01528735Boehringer Ingelheim25